Lataa...
Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity
The clinical benefit of MAPK pathway inhibition in BRAF-mutant melanoma patients is limited by the development of acquired resistance. Using drug-naïve cell lines derived from tumor specimens, we established a preclinical model of melanoma resistance to vemurafenib or trametinib to provide insight i...
Tallennettuna:
| Julkaisussa: | Cells |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7017165/ https://ncbi.nlm.nih.gov/pubmed/31936151 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9010142 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|